Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Dr. Martens Plc LSE:DOCS London Ordinary Share GB00BL6NGV24 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -3.00 -1.26% 234.40 951,579 16:35:24
Bid Price Offer Price High Price Low Price Open Price
234.60 235.00 242.00 229.20 229.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Retailers 908.30 214.30 18.10 13.0 2,344
Last Trade Time Trade Type Trade Size Trade Price Currency
18:28:37 O 1,730 238.99 GBX

Dr. Martens (DOCS) Latest News (2)

More Dr. Martens News
Dr. Martens Investors    Dr. Martens Takeover Rumours

Dr. Martens (DOCS) Discussions and Chat

Dr. Martens Forums and Chat

Date Time Title Posts
02/6/202220:30Dr. Martens66
14/2/202116:55Dr Martens - just mucking about (please ignore)10

Add a New Thread

Dr. Martens (DOCS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-07-01 17:28:37238.991,7304,134.53O
2022-07-01 16:59:26236.3834,47381,485.55O
2022-07-01 16:40:05235.1811,80327,758.06O
2022-07-01 16:39:36235.182,6056,126.39O
2022-07-01 16:37:46236.091,2102,856.74O
View all Dr. Martens trades in real-time

Dr. Martens (DOCS) Top Chat Posts

DateSubject
02/7/2022
09:20
Dr. Martens Daily Update: Dr. Martens Plc is listed in the General Retailers sector of the London Stock Exchange with ticker DOCS. The last closing price for Dr. Martens was 237.40p.
Dr. Martens Plc has a 4 week average price of 229.20p and a 12 week average price of 174.70p.
The 1 year high share price is 477.20p while the 1 year low share price is currently 174.70p.
There are currently 1,000,000,100 shares in issue and the average daily traded volume is 1,088,410 shares. The market capitalisation of Dr. Martens Plc is £2,344,000,234.40.
02/6/2022
18:08
shooter mcgavin: General share chat on telegram - Bulls/Bears welcome hxxps://t.me/+uvhRj0z103ZjMDQ0
01/6/2022
12:05
stpalm: Thanks for those posts linton5 I was going to make a small starter position and you made me remember the gap filling which usually happens. Per seems to be reasonable now though at 12 and stocko says price to free cashflow is 22. Tempting!
25/5/2022
17:57
castleford tiger: As a result of the Placing, IngreLux S.àr.l. will hold 364,142,440 ordinary shares, representing approximately 36.4% of Dr. Martens' issued share capital. Even after selling the last lot they still hold 36% of the company worth 720m How did they get this away? Who chased it higher ? At a market cap of 1 billion it looks too much. Further to fall in my opinion. Tiger
24/2/2022
16:17
essentialinvestor: Hi Phil, you are probably aware there remains a large shareholder here who could potentially want a complete exit, if so, that will take time and a shedload of shares for any buyers to absorb.
23/2/2022
14:52
philanderer: Questor: Why Dr Martens is a good fit Questor share tip: shift to online sales and loyal customer following could catalyse this stock https://www.telegraph.co.uk/investing/shares/questor-falling-share-price-improving-growth-outlook-make-dr/
14/1/2022
08:54
essentialinvestor: Thanks for the views folks. Valuation still looks on the high side as recently mentioned on the SHA board. To get down towards £1 a share would require a significant miss on consensus imv (a possibility). That number is currently near £200 million FY pre tax. There are clear inflationary headwinds so a lot depends on navigating those and resultant margins, keeping on a watchlist until at least the next update. Like the brand but questions remain.
10/12/2021
13:46
km18: Dr. Martens plc posted interims for the 6 months ended September 2021 titled, “Strong first half performance; confident in full year expectations.” Not a bad summary. Revenue grew 16% and PBT of £61.3m was up 46%. The company also declared its inaugural interim dividend, at 1.22p per share, equating to a 25% earnings payout ratio. The outlook also appears to be encouraging, momentum seen in retail in the first half has continued to strengthen during October and November and management are confident in achieving market expectations for FY22. For the medium-term management continue to anticipate mid-teens revenue growth with a medium-term target of 30% EBITDA margin. Valuation is a little rich, forward PE ratio over 20, and the share price lacks momentum and continues to trade sideways through 2021. A decent company, but one to monitor for now...from WealthOracleAM https://wealthoracle.co.uk/detailed-result-full/DOCS/278
24/5/2021
22:29
mj19: At a share price of 457p, the shares trade on a PE of 30 times 2022F earnings per share (EPS). This compares with global athleisure powerhouses Nike and Adidas on 34 times and 26 times, respectively.This is a punchy valuation from which it is very easy to construct a bear case. The sustainability of the current enthusiasm for the brand is a valid concern, but if management is only vaguely right about the future potential of the business then the shares could turn out to be a very good buy from here. It does not look like a business that has been fattened up for sale.
01/5/2021
09:55
mj19: Comparing with valuation multiples for 2022 for peers Canada Goose, Crocs, Deckers, Moncler, and VF Corp, this would imply fair value of 267-543p for the shares, Barclays said."We look for management to build a track record as a public company before arguing DOCS deserves to trade at the top of this range."Revenues and earnings per share are forecast by RBC to grow 14%-plus and 22%-plus out to 2025, while free cash flow "should improve broadly in line with earnings, whilst a progressive 25-35% dividend payout from 1H22 is helpful".On RBC's estimates, the shares trade at 35 times forecast 2021 earnings compared to a peer group at 30 times.
29/1/2021
07:36
bigbigdave: 29 January 2021 Dr. Martens plc Announcement of Offer Price Offer Price set at 370 pence per Share Following the intention to float announcement on 18 January 2021, Dr. Martens plc (the "Company" or "Dr. Martens"), today announces the successful pricing of its initial public offering (the "Offer") at 370 pence per Share (the "Offer Price"). Based on the Offer Price, Dr. Martens' market capitalisation will be approximately GBP3.7 billion at the commencement of conditional dealings on the main market of the London Stock Exchange. Kenny Wilson, CEO of Dr. Martens, said: "We have been delighted by the strong levels of interest, engagement and support from such a high quality selection of institutional investors. The successful transformation of Dr. Martens is a great story, and what is even more exciting is the huge potential ahead. We are proud to take our place as a London listed company, both delivering as a successful plc and more importantly continuing to grow our Brand around the world."
Dr. Martens share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
DOCS
Dr. Marten..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220702 14:58:04